Among individuals with comparable levels of LDL-c, individuals with monogenic FH had the highest risk for composite CVD events followed by individuals with polygenic hypercholesterolemia compared to those with nongenetic hypercholesterolemia.

The open-label TAUSSIG study evaluated treatment with evolocumab during a median follow-up of 4.1 years and found a similar safety profile and good LDL-c lowering in HoFH and HeFH patients

The FIND FH is a machine learning model that identified a large number of individuals with probable FH who had not previously been diagnosed in two distinct types of large medical databases.

AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

Final results from the open-label OSLER-1 study on evolocumab show long-term reduction in LDL-C levels without attenuation of the LDL-lowering effect and consistent safety and tolerability profiles during 5-years.

CSI Paris Cilie van 't Klooster asks prof. Mach to summarize the most important changes in the 2019 ESC/EAS dyslipidemia guidelines.

Long-term follow-up of persons with FH who started statin therapy in childhood shows that progression of cIMT was slowed to the rate seen in unaffected siblings, and CV event risk was reduced.

The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.

The ELIPSE HoFH trial met its primary endpoint, showing that evinacumab lowered LDL-c by 49% from baseline in HoFH patients already on other lipid-lowering therapies, including PCSK9 inhibitors.

Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

In >1 million blood donors, the prevalence of FH was similar to the estimated prevalence of FH in the general population. This suggests that donor screening may represent a new approach for FH screening and intervention.

EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.